- Home
- DGICA vs URGN Comparison
DGICA vs URGN Comparison
Compare DGICA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICA
- URGN
- Stock Information
- Founded
- DGICA 1986
- URGN 2004
- Country
- DGICA United States
- URGN United States
- Employees
- DGICA N/A
- URGN N/A
- Industry
- DGICA Property-Casualty Insurers
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- DGICA Finance
- URGN Health Care
- Exchange
- DGICA Nasdaq
- URGN Nasdaq
- Market Cap
- DGICA 516.7M
- URGN 465.9M
- IPO Year
- DGICA N/A
- URGN 2017
- Fundamental
- Price
- DGICA $14.55
- URGN $10.19
- Analyst Decision
- DGICA
- URGN Strong Buy
- Analyst Count
- DGICA 0
- URGN 5
- Target Price
- DGICA N/A
- URGN $44.50
- AVG Volume (30 Days)
- DGICA 78.1K
- URGN 487.3K
- Earning Date
- DGICA 02-20-2025
- URGN 03-13-2025
- Dividend Yield
- DGICA 4.70%
- URGN N/A
- EPS Growth
- DGICA 148.60
- URGN N/A
- EPS
- DGICA 0.74
- URGN N/A
- Revenue
- DGICA $979,119,004.00
- URGN $89,363,000.00
- Revenue This Year
- DGICA N/A
- URGN $12.21
- Revenue Next Year
- DGICA $5.78
- URGN $46.19
- P/E Ratio
- DGICA $19.71
- URGN N/A
- Revenue Growth
- DGICA 7.44
- URGN 15.64
- 52 Week Low
- DGICA $12.26
- URGN $9.78
- 52 Week High
- DGICA $17.00
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- DGICA 31.80
- URGN 38.51
- Support Level
- DGICA $14.17
- URGN $10.12
- Resistance Level
- DGICA $15.60
- URGN $10.91
- Average True Range (ATR)
- DGICA 0.30
- URGN 0.56
- MACD
- DGICA -0.03
- URGN -0.01
- Stochastic Oscillator
- DGICA 26.57
- URGN 20.71
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.